Q32 Bio has launched with $46m from investors including Sanofi Ventures and Children’s Hospital Colorado to target autoimmune and inflammatory diseases.
US-based biologics developer Q32 Bio has disclosed a $46m series A round that included pharmaceutical firm Sanofi and healthcare provider Children’s Hospital Colorado.
Venture capital firm Atlas Venture had already incubated the startup and provided seed funding. It led the series A round, which was also backed by OrbiMed Advisors, Abingworth and University of Colorado.
Sanofi and Children’s Hospital Colorado invested in the round through Sanofi Ventures and Children’s Hospital Colorado Center for Innovation respectively.
Q32 Bio is working on…
